

902,074
EAST

| L Number | Hits | Search Text | DB | Time stamp |
|----------|------|--|---|---------------------|
| 1 | 61 | (424/176.1).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:33 |
| 2 | 110 | (424/177.1).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:33 |
| 3 | 91 | (530/390.1).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:33 |
| 4 | 132 | (530/390.5).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:37 |
| 5 | 643 | (530/416).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:37 |
| 6 | 877 | ((424/176.1).CCLS.) or ((424/177.1).CCLS.) or ((530/390.1).CCLS.) or ((530/390.5).CCLS.) or ((530/416).CCLS.) | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:38 |
| 7 | 633 | (immunoglobulin\$1 adj G).ti,ab,clm. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:39 |
| 8 | 5155 | IgG\$1.ti,ab,clm. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:39 |
| 9 | 5502 | ((immunoglobulin\$1 adj G).ti,ab,clm.) or IgG\$1.ti,ab,clm. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:39 |
| 10 | 76 | ((424/176.1).CCLS.) or ((424/177.1).CCLS.) or ((530/390.1).CCLS.) or ((530/390.5).CCLS.) or ((530/416).CCLS.) and (((immunoglobulin\$1 adj G).ti,ab,clm.) or IgG\$1.ti,ab,clm.) | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2002/11/02 15:40 |

902,174
MEDLINE
11/2/02

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul82das

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:04:46 ON 02 NOV 2002

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 15:05:00 ON 02 NOV 2002

FILE LAST UPDATED: 1 NOV 2002 (20021101/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

If you received SDI results from MEDLINE on October 8, 2002, these may have included old POPLINE data and in some cases duplicate abstracts. For further information on this situation, please visit NLM at:
http://www.nlm.nih.gov/pubs/techbull/so02/so02_popline.html

To correct this problem, CAS will remove the POPLINE records from the MEDLINE file and process the SDI run dated October 8, 2002 again.

Customers who received SDI results via email or hard copy prints on October 8, 2002 will not be charged for this SDI run. If you received your update online and displayed answers, you may request a credit by contacting the CAS Help Desk at 1-800-848-6533 in North America or 614-447-3698 worldwide, or via email to help@cas.org

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s octagam

L1 7 OCTAGAM

=> d l1 1-7 au ti so py

L1 ANSWER 1 OF 7 MEDLINE

AU Alekseeva E I; Shakhbazian I E; Zholobova K B

TI [Effectiveness of systemic immunoglobulins in the treatment of the systemic variants of juvenile rheumatoid arthritis].
Effektivnost' lecheniia vnutrivennykh immunoglobulinom bol'nykh so sistemnymi variantami iuvenial'nogo revmatoidnogo artrita.

SO KLINICHESKAIA MEDITSINA, (2001) 79 (2) 26-9.

Journal code: 2985204R. ISSN: 0023-2149.

PY 2001

L1 ANSWER 2 OF 7 MEDLINE

AU Barinov A V; Ol'mezov V V

TI [Use of **octagam** and pentaglobin in the treatment of severe sepsis in the neonatal period].

Primenenie oktagama i pentaglobina v lechenii tiazhelogo sepsisa v neonatal'nom periode.

SO ANESTEZIOLOGIIA I REANIMATOLOGIIA, (1999 May-Jun) (3) 59-60.

Journal code: 7705399. ISSN: 0201-7563.

PY 1999

L1 ANSWER 3 OF 7 MEDLINE
 AU Fiane A E; Videm V; Mellbye O J; Foerster A; Geiran O R; Gladhaug I P;
 TI Immunoglobulin prolongs survival of pig kidneys perfused ex vivo with
 human blood.
 SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY, (1998 Jun) 47 (6) 568-74.
 Journal code: 0323767. ISSN: 0300-9475.
 PY 1998

L1 ANSWER 4 OF 7 MEDLINE
 AU Mollnes T E; Andreassen I H; Hogasen K; Hack C E; Harboe M
 TI Effect of whole and fractionated intravenous immunoglobulin on complement
 in vitro.
 SO MOLECULAR IMMUNOLOGY, (1997 Jul) 34 (10) 719-29.
 Journal code: 7905289. ISSN: 0161-5890.
 PY 1997

L1 ANSWER 5 OF 7 MEDLINE
 AU Brenner B
 TI Clinical experience with **Octagam**, a solvent detergent (SD) virus
 inactivated intravenous gammaglobulin.
 SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, (1996 May-Jun) 14 Suppl 15 S115-9.
 Journal code: 8308521. ISSN: 0392-856X.
 PY 1996

L1 ANSWER 6 OF 7 MEDLINE
 AU Biesert L
 TI Virus validation studies of immunoglobulin preparations.
 SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, (1996 May-Jun) 14 Suppl 15 S47-52.
 Journal code: 8308521. ISSN: 0392-856X.
 PY 1996

L1 ANSWER 7 OF 7 MEDLINE
 AU Theron A J; Joone G K; Anderson R
 TI Comparison of the composition and opsonic activities of imported and South
 African-manufactured intravenous and intramuscular immunoglobulin
 preparations.
 SO SOUTH AFRICAN MEDICAL JOURNAL, (1994 Nov) 84 (11) 743-6.
 Journal code: 0404520. ISSN: 0038-2469.
 PY 1994

=> d 11 4-6 bib ab

L1 ANSWER 4 OF 7 MEDLINE
 AN 1998090043 MEDLINE
 DN 98090043 PubMed ID: 9430199
 TI Effect of whole and fractionated intravenous immunoglobulin on complement
 in vitro.
 AU Mollnes T E; Andreassen I H; Hogasen K; Hack C E; Harboe M
 CS Department of Immunology and Transfusion Medicine, Nordland Central
 Hospital, Bodo, Norway.. tomeirik@fagmed.uit.no
 SO MOLECULAR IMMUNOLOGY, (1997 Jul) 34 (10) 719-29.
 Journal code: 7905289. ISSN: 0161-5890.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199801
 ED Entered STN: 19980217
 Last Updated on STN: 19980217
 Entered Medline: 19980130

AB Intravenous immunoglobulins (IVIG) are increasingly used for treatment of inflammatory diseases, and the modulation of complement may contribute to some of its beneficial effects. IVIG may bind C1q and activated C3 and C4, and enhance inactivation of C3b. We have previously shown that IVIG inhibited complement-mediated lysis solely via its Fc part through interaction with the classical pathway. In the present study we have investigated whole IVIG (**Octagam**, and Sandoglobulin) and the monomer, dimer and multimer fractions of **Octagam** with respect to complement activation in serum and inhibition of complement lysis of red cells. The isolated fractions were found to be stable, homogeneous (monomer, dimer or multimer) and pure (virtually only IgG). Both whole IVIG and its fractions significantly activated complement in serum and inhibited hemolysis compared with human albumin. These effects were most pronounced in the monomer, less in the multimer and least in the dimer fraction. The complement activation was shown to be mediated through the classical pathway since formation of C1rs-C1inh complexes and C4bc were increased, in contrast to Bb. Surprisingly, heat aggregation of **Octagam** was not followed by a corresponding increase in complement activation, as would be expected, unless it was dialysed before heating, suggesting that it is stabilized to avoid excess activation. In conclusion, the results support the hypothesis that IVIG causes a mild activation of complement in vitro. We suggest that this effect may contribute to the complement inhibitory properties of IVIG by diverting complement deposition from the target to the fluid phase.

L1 ANSWER 5 OF 7 MEDLINE
AN 96426679 MEDLINE
DN 96426679 PubMed ID: 8828958
TI Clinical experience with **Octagam**, a solvent detergent (SD) virus inactivated intravenous gammaglobulin.
AU Brenner B
CS Institute of Hematology, Rambam Medical Center, Haifa, Israel.
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, (1996 May-Jun) 14 Suppl 15 S115-9. Journal code: 8308521. ISSN: 0392-856X.
CY Italy
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199612
ED Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961210
AB OBJECTIVE: The safety and efficacy of **Octagam**, a solvent detergent (SD) virus inactivated intravenous gammaglobulin, were evaluated in 54 patients who received 301 infusions of **Octagam** for a total amount of 9301 grams, during 24 months. METHODS: Adverse reactions during and after **Octagam** infusion were carefully recorded. Serum IgG and ALT levels were recorded monthly. Antibodies to HIV, HBV and HCV were recorded every 3 months. RESULTS: In 22 chronic lymphocytic leukemia patients and 4 multiple myeloma patients, the monthly infusion of 0.4 gr/kg **Octagam** proved safe and effective in increasing IgG levels and potentially reducing the rate of serious bacterial infections. In 20 patients with ITP, infusion of 2 gr/kg of **Octagam** was safe and effective in increasing the platelet count and in arresting spontaneous bleeding or preventing bleeding prior to surgical procedures. In 8 patients with the antiphospholipid syndrome monthly infusions of **Octagam** were found to be safe. Adverse reactions following **Octagam** infusion were uncommon, generally mild and all were transient. Viral safety assays for HIV, HBV and HCV were all negative. CONCLUSION: **Octagam** is a safe intravenous gammaglobulin effective in patients with secondary hypogammaglobulinemia and ITP.

L1 ANSWER 6 OF 7 MEDLINE

AN 96426669 MEDLINE
 DN 96426669 PubMed ID: 8828948
 TI Virus validation studies of immunoglobulin preparations.
 AU Biesert L
 CS Virological Research Group, Octapharma AG, Frankfurt, Germany.
 SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, (1996 May-Jun) 14 Suppl 15 S47-52.
 Journal code: 8308521. ISSN: 0392-856X.
 CY Italy
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; AIDS
 EM 199612
 ED Entered STN: 19970128
 Last Updated on STN: 19970128
 Entered Medline: 19961210

AB OBJECTIVE: A validation study of the viral safety of a new polyvalent intravenous immunoglobulin (**OCTAGAM**) according to EU-guideline III/8115/89-EN and the requirements of the Federal Agency for Sera and Vaccines in Germany was undertaken in May 1994. The following processing steps were analyzed: Cohn-Oncley fractionation, solvent/detergent (SD) treatment, pH 4 exposure, storage of the final product at low pH and immune neutralisation. METHODS: The following virus reduction factors were obtained: Cohn-Oncley fractionation: HIV-1 > 5.50; sindbis virus > 6.36; pseudorabies virus > 7.28; coxsackievirus-B6 2.70; poliovirus-1 > 3.80; SV40 > 5.51. Solvent/Detergent treatment: HIV-1 > 6.03; sindbis virus > 7.80; pseudorabies virus > 8.38. pH 4 exposure: HIV-1 > 8.60; sindbis virus > 8.94; pseudorabies virus > 5.95; coxsackievirus-B6 2.72; SV40 1.15. Immune neutralisation: coxsackievirus-B6 > 4.98, polio-virus-1 > 5.14, HAV > 3.44, HSV-1 > 5.92. The following virus reduction factors were calculated for the final product: HIV-1 > 20.13; sindbis virus > 23.10; pseudorabies virus > 21.61; coxsackievirus-B6 > 10.4; poliovirus-1: > 8.94; HAV > 3.44; SV40 > 6.66. CONCLUSION: The results of our validation studies demonstrated that in addition to Cohn fractionation and immune neutralization, the two additional steps of solvent/detergent treatment and pH 4 exposure, mainly contribute to the safety of **OCTAGAM** with respect to both enveloped and non-enveloped viruses.

=> save temp

ENTER L#, L# RANGE, ALL, OR (END):11

L1 IS NOT A VALID L#, L# RANGE, OR ALL

Enter a valid L-number or L-number range for the items to be saved or ALL to SAVE all session queries as an L-number list. To see all L-numbers defined in this session, enter END. Then enter DISPLAY HISTORY at an arrow prompt (=>).

ENTER L#, L# RANGE, ALL, OR (END):11

ENTER NAME OR (END):octagam/a

ANSWER SET L1 HAS BEEN SAVED AS 'OCTAGAM/A'

=> log y

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 3.23 | 3.44 |

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 15:08:45 ON 02 NOV 2002